Amazon splits up the Wondery podcast network and lays off about 110 employees
Amazon told Bloomberg it will continue to produce podcasts, though their place within the company will be restructured. The more narrative-focused podcasts under the Wondery brand, such as American Scandal and Business Wars , will merge with Amazon's Audible team. Some of these podcasts will retain Wondery branding, and the Wondery Plus app will remain active. Subscribers to Wondery Plus get early access to some podcast episodes through the app, though it's unclear at this point what functionalities will remain in the app, and which will be absorbed by Audible.
Meanwhile, the celebrity-hosted shows such as New Heights with Jason and Travis Kelce and Armchair Expert with Dax Shepard will be rolled into a new team that Amazon is calling Creator Services. According to Bloomberg , a main focus of this new team will be selling large sponsorships. These titles are part of a growing trend toward video podcasts that have helped make YouTube the go-to platform for podcast consumption.
Steve Boom, VP for Audio, Twitch and Games at Amazon, addressed the changes in a memo (published by Deadline ) sent to Amazon employees. "The podcast landscape has evolved significantly over the past few years. As video podcasting has grown in popularity, we have learned that creator-led, video-integrated shows have different audience needs and require distinct discovery, growth and monetization strategies compared with audio-first, narrative series," he wrote.
Employees who were let go as part of these changes were notified Monday, though Amazon spokesperson Alice Zhou told The Verge that "many of the impacted employees" would be moved to "other parts of Amazon."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Pfizer Lifts Profit View as Cuts Offset Flat Sales Outlook
(Bloomberg) -- Pfizer Inc. raised its profit forecast for the year, with the drugmaker's ongoing cost cuts helping to make up for a lack of expected sales growth. PATH Train Service Resumes After Fire at Jersey City Station Mayor Asked to Explain $1.4 Billion of Wasted Johannesburg Funds Chicago Curbs Hiring, Travel to Tackle $1 Billion Budget Hole All Hail the Humble Speed Hump The company's stock rose as much as 5.4% in New York Tuesday as investors look for good news after a decline in demand for the company's Covid products forced the drugmaker to reshape its business. Adjusted profits will be between $2.90 to $3.10 per share in 2025, the New York-based company said in a statement, an increase of 10 cents per share over its prior projection. The company didn't increase its sales expectations of $61 billion to $64 billion, citing a cautious view of its Covid business heading into the fall. The midpoint of the company's sales outlook represents a decline from 2024. 'It's marginally positive,' Mizuho analyst Jared Holz said. 'And with the pharmaceutical industry the toughest it's been in a long time, that's good enough.' Pfizer is in the process of rebuilding in the aftermath of the pandemic, slashing about $7.2 billion from its spending and betting on an unproven pipeline of new medicines to make up for the stagnant sales of its aging products. The company faces a roughly $15 billion patent cliff by the end of the decade, and investors remain skeptical its pipeline of new medicines can eventually replace the lost revenue. The drugmaker is actively looking for deals that would bring in new drugs, Chief Executive Officer Albert Bourla said in an interview, adding that Pfizer's head of strategy recently made a trip to China where he met with about 35 biotech firms. The company has allocated about $13 billion for transactions in 2025, Bourla said. 'But we will be very disciplined with our capital,' he said, preferring to strike a series of small deals rather than spending billions on a single one. Tariff Threat Adding to pressure, the entire pharmaceutical industry faces the threat of sector-specific tariffs and policies that would restrict what they can charge for medicines in the US. As Pfizer was reporting its second-quarter earnings on Tuesday, President Donald Trump said in a television interview pharma tariffs would be announced 'within the next week or so.' On Thursday, Trump also sent letters to 17 of the largest drugmakers, demanding they slash the price of medicines for US customers. Bourla was one of the executives to receive a personal letter from the president. Pfizer has held 'productive discussions' with Trump and his administration since then, Bourla said on a conference call with analysts Tuesday. He said he has spoken up for industry priorities, including reining in pharmaceutical middlemen and making changes to a Joe Biden-era law that allows the government to negotiate certain drug prices. Bourla declined to provide further details but said he and Trump have 'a special relationship from the times of Covid,' when Pfizer worked with the administration to develop its vaccine. 'There is no scenario that we have not assessed,' Bourla said of potential tariffs and pricing restrictions. 'There is no scenario that we have not built mitigation plans for.' In its earnings report, the company said its new guidance accounts for existing tariffs on imports from China, Canada and Mexico. Pfizer has also factored in 'potential price changes this year' that may result from Trump's demands. Pfizer relies on a global network of manufacturing sites to supply its drugs. Profit Projection The drugmaker attributed its increased 2025 profit projection to its ongoing cost cuts, the effects of the weakening dollar, and an improvement in its tax rate. Chief Financial Officer David Denton said he foresees additional cuts over the next two years. The company's second-quarter sales were $14.7 billion, beating average estimates by more than $1 billion. Pfizer's biggest drug, the more than decade-old blood thinner Eliquis, surpassed expectations and the pneumonia vaccine Prevnar beat the Street's view. Sales of the company's vaccine and pill for Covid came in well above estimates. Demand for those products has precipitously declined since 2022. Bourla, who took over as CEO in 2019, has declined to say how long he intends to remain in his role at Pfizer. Developing a vaccine for Covid constituted 'the biggest success that anyone could dream of having,' he said, which will undoubtedly be his legacy at the company. 'What I aspire to is maybe to do it once more,' Bourla said. (Updates with additional details, executive interviews starting in fourth paragraph.) Russia's Secret War and the Plot to Kill a German CEO AI Flight Pricing Can Push Travelers to the Limit of Their Ability to Pay Government Steps Up Campaign Against Business School Diversity What Happens to AI Startups When Their Founders Jump Ship for Big Tech How Podcast-Obsessed Tech Investors Made a New Media Industry ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 minutes ago
- Yahoo
McDonald's expected to reverse sales slump, paint rosier outlook with Snack Wrap's return
McDonald's (MCD) is expected to report a return to sales growth Wednesday morning when the company releases results for its fiscal second quarter. Global comparable sales — or sales at restaurants in operation for more than one year — are expected to grow 2.49%, led by international developmental markets, up 3.64%, and the US, up 2.33%, according to estimates from Bloomberg. The company's US comp sales fell 3.6% in its fiscal first quarter reported back in May, while global comparable sales fell 1%. Second quarter revenue is expected to clock in at $6.70 billion, according to Bloomberg data, up from $6.49 billion a year ago when CEO Chris Kempczinski told investors it was "clear that our value leadership gap has recently shrunk." Adjusted earnings per share are expected to tick higher too at $3.14, up from $2.97 this time period last year. Year to date, McDonald's stock is up 3.5%, against a roughly 7% gain for the S&P 500. Analysts are optimistic the company will also paint a rosier outlook for the second half of the year, as it launched the return of the Snack Wrap on July 10, which is part of its current quarter. McDonald's reaffirmed its 2025 fiscal year financial targets back in May. "We believe the July commentary with the recent launch of expanded value and Chicken Snack Wrap at $2.99 should have same-store sales growth back in [the] mid-single digit range with positive traffic," Jefferies analyst Andy Barish said in a note. Wall Street expects same-store sales to grow 1.86% for the full fiscal year, with US same-store sales up 1.20%. In its most recent quarter, McDonald's sought to emphasize its value leadership as it leaned into offerings like the Meal Deal, innovations like its McCrispy Chicken Strips, and marketing with its Minecraft Movie promotion. The company also continues to move further away from the E. coli outbreak last fall that weighed on sales. "We believe MCD will continue to build the narrative that it is shifting into a higher gear as it relates to product innovation, collaborations, and IP tie-ins ... which could supplement value as a traffic driver and lead to balanced franchisee economics, accelerating unit growth, and sustained same-store sales growth outperformance versus the industry," Citi analyst Jon Tower said in a note to clients. Brooke DiPalma is a senior reporter for Yahoo Finance. Follow her on X at @BrookeDiPalma or email her at bdipalma@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Tom's Guide
3 minutes ago
- Tom's Guide
Amazon may bring ads to Alexa+ in least surprising move ever
Up until now Amazon has mostly avoided stuffing Alexa with ads, but according to a report from Mashable, Amazon CEO Andy Jassy broached the idea of delivering ads in Alexa Plus during the company's recent earnings call. Alexa Plus is the company's premium AI assistant that is supposed to be more naturally conversational than the previous Alexa. Jassy reportedly said that there is a "significant financial opportunity" in delivering ads via Alexa Plus. "I think over time, there will be opportunities, you know, as people are engaging in more multi-turn conversations to have advertising play a role — to help people find discovery and also as a lever to drive revenue," Jassy said, as found in the earnings call transcript. The new Alexa, introduced in February, has "enhanced" conversational abilities that are meant to put it on other AI assistants like Google's Gemini or ChatGPT. With improved memory its supposed to remember your details and help with managing tasks like booking tables for date night or buying groceries. Currently, Amazon offers a $19.99 a month subscription for non-Prime members. Prime subscribers, which costs $14.99 a month or $139 annually, can get Alexa+ for free Many Amazon devices are Alexa+ capable, though not all. However, Alexa has largely been an ad-free experience for the last decade since it was introduced. Perhaps it's not too surprising that Amazon would consider adding some kind of revenue procuring element to its AI assistant. The company has struggled for years to upgrade Alexa as other AI assistants surpassed Amazon who introduced chatbot assistants to the market. Get instant access to breaking news, the hottest reviews, great deals and helpful tips. Largely, integrating ads is a revenue ploy to recoup some of the billions Amazon has burned in trying to turn its smart assistant around. Both Google and OpenAI have explored putting ads in Gemini and ChatGPT. OpenAI teased the idea in December of 2024 though the company stepped back from the idea in the same sentence. Amazon has not officially made moves to add commercials to Alexa+ conversations, but Jassy framed the idea as helpful. It would supposedly assist you in finding products that you might want to buy. With no set plans, it's worth keeping an eye on Alexa+ to see how or if Amazon actually follows through with Jassy's idea and how obtrusive they'll become. Hopefully they'll be skippable at the very least.
